Drug Type Autologous CAR-T |
Synonyms |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), Immunologic cytotoxicity + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | GB | 15 Dec 2021 | |
Neoplasms | Phase 2 | AU | 15 Dec 2021 | |
Neoplasms | Phase 2 | IL | 15 Dec 2021 | |
Neoplasms | Phase 2 | CA | 15 Dec 2021 | |
Neoplasms | Phase 2 | NL | 15 Dec 2021 | |
Neoplasms | Phase 2 | FR | 15 Dec 2021 | |
Neoplasms | Phase 2 | JP | 15 Dec 2021 | |
Neoplasms | Phase 2 | US | 15 Dec 2021 | |
Neoplasms | Phase 2 | DE | 15 Dec 2021 | |
B-Cell Lymphoma | Phase 1 | US | 27 Oct 2021 |